AstraZeneca PLC (AZN)vsDefinitive Healthcare Corp (DH)
AZN
AstraZeneca PLC
$183.02
+1.10%
HEALTHCARE · Cap: $284.30B
DH
Definitive Healthcare Corp
$0.76
-1.14%
HEALTHCARE · Cap: $85.30M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 25267% more annual revenue ($60.44B vs $238.26M). AZN leads profitability with a 17.2% profit margin vs -71.5%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
DH
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+5.9%
Fair Value
$194.57
Current Price
$183.02
$11.55 discount
Margin of Safety
+78.5%
Fair Value
$7.87
Current Price
$0.76
$7.11 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
ROE of -116.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : DH
The strongest argument for DH centers on Price/Book.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : DH
The primary concerns for DH are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while DH is a turnaround play — different risk/reward profiles.
DH carries more volatility with a beta of 1.33 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 37/100), backed by strong 17.2% margins and 12.5% revenue growth. DH offers better value entry with a 78.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Definitive Healthcare Corp
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Definitive Healthcare Corp (DH) is a premier provider of comprehensive data and analytics solutions tailored for the healthcare sector, serving a broad spectrum of clients, including pharmaceutical firms, payers, and healthcare providers. The company leverages vast datasets and advanced real-time analytics to drive operational efficiency and provide strategic insights, ultimately enhancing patient outcomes. Positioned at the forefront of a rapidly evolving healthcare landscape, Definitive Healthcare is dedicated to delivering innovative, data-centric solutions that not only optimize operational performance but also confer competitive advantages to its partners. As demand for sophisticated healthcare analytics surges, DH is poised to be an influential player in redefining healthcare delivery.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?